טוען...

Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin

Despite the clinical success of platinum-containing drugs in the treatment of solid tumors, acquired resistance remains a major obstacle. We previously identified a group of novel transplanaramine or transplatinum compounds based on distinct activity profiles in the NCI-60 panel. In the present stud...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Murphy, Robert F., Komlodi-Pasztor, Edina, Robey, Rob, Balis, Frank M., Farrell, Nicholas P., Fojo, Tito
פורמט: Artigo
שפה:Inglês
יצא לאור: Landes Bioscience 2012
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3679288/
https://ncbi.nlm.nih.gov/pubmed/22333583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.11.5.19447
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!